Skip to main content
. 2014 May 2;4:4874. doi: 10.1038/srep04874

Figure 3. c-Abl inhibitor, nilotinib protects against MPTP-induced dopamine depletion.

Figure 3

Nilotinib or vehicle administered mice were subjected to acute MPTP injections (20 mg/kg, MPTP free base X 4, every 2 h). Striatal dopamine (DA) and metabolites levels were analysed 7 days after the last MPTP injection by HPLC-ECD analysis. (a) Nilotinib rescues DA loss and (b) DOPAC in the striatum of MPTP mice. (c) Striatal levels of HVA and (d) 3MT were restored in mice treated with nilotinib. (e) There is a significant decrease in DA turnover [(DOPAC+HVA/DA) and (f) (DOPAC+3MT/DA)] in the striatum of nilotinib treated mice. Error bars represent the mean ± SEM, n = 5 mice per group. Two-way ANOVA was used to test significant and followed with post-hoc Bonferroni test to compare with the multiple group. **p<0.0002, *** p<0.0001 for MPTP with compare control group, #p<0.05, ### p<0.001 for Nil+ MPTP compared MPTP group. (ns: not significant).